COLCHICORT Trial Save
The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors.
A post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP arthritis, also examined associations with sustained arthritis resolution on day 3.
Overall, 43/89 (48.3%) patients were definite responders. Resolution of CCP arthritis on day 3 was associated with:
- being hospitalised for stroke (9/43) (p=0.04),
- age ≥ 80 years old (39/43)(p=0.045)
- dyslipidemia (25/43) (p=0.03)
- acute arthritis of the wrists (OR 4.06 95%CI [1.21; 15.50.85])
Poor responders were more commonly:
- hospitalised for acute arthritis (22/43) (p<0.001)
- Treated with colchicine (OR 0.31 95%CI [0.11; 0.83])
- diuretic use (OR 0.23 95%CI [0.097; 0.95])
By multiple logistic regression modeling, gastrointestinal adverse events with colchicine: male sex (OR 0.33 95% CI (0.07; 1.29) and diabetes (OR 0.24 95%CI (0.030; 1.24)) seemed protective while statin use (OR 3.54 95%CI (0.83; 18.82) seemed associated with their occurrence.
Overall, colchicine was associated with poorer efficacy, and was impacted by a dual effect on its safety and efficacy by medications and associated conditions.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.